Introduction
Wolfgang Marguerre’s net worth is estimated at $7.8 billion in 2026, according to Forbes. His fortune was built primarily through Octapharma, the privately owned pharmaceutical company he co-founded in Switzerland in 1983 and has continued to lead as Chairman and CEO.
Marguerre’s wealth story is different from that of entertainment celebrities or publicly traded-company executives. His fortune is closely tied to long-term ownership of a private healthcare business that has grown into a global producer of human protein medicines.
Octapharma reported €3.64 billion in net sales and €577 million in operating income for 2025, marking another record year for the company. It had 11,126 employees worldwide at the end of 2025.
Quick Facts
| Category | Details |
| Full Name | Wolfgang Marguerre |
| Date of Birth | June 4, 1941 |
| Age | 85 |
| Birthplace | Heidelberg, Germany |
| Nationality | German |
| Profession | Pharmaceutical entrepreneur and business executive |
| Best Known For | Founder, Chairman and CEO of Octapharma |
| Estimated Net Worth | $7.8 billion |
| Primary Source of Wealth | Pharmaceuticals |
| Company | Octapharma |
| Headquarters | Lachen, Switzerland |
| Marital Status | Married |
| Children | Three |
| Education | Heidelberg University; INSEAD |
| Residence | Heidelberg, Germany |
Forbes estimated Wolfgang Marguerre and his family at $7.8 billion as of September 7, 2026.
Wolfgang Marguerre Net Worth
Wolfgang Marguerre and his family have an estimated net worth of $7.8 billion, based on Forbes’ real-time estimate dated September 7, 2026.
The figure should be understood as an estimated family fortune rather than a publicly audited personal balance sheet. Octapharma is privately owned, so there is no publicly traded share price that allows investors to calculate the value of Marguerre’s holdings in real time.
What is behind Marguerre’s fortune?
The central asset behind his wealth is his long-standing ownership interest in Octapharma.
Octapharma describes itself as the world’s largest privately owned and independent plasma fractionator. The company is headquartered in Lachen, Switzerland, and has been family-owned since its founding in 1983.
The company’s business focuses on human protein medicines derived from human plasma and human cell lines. Its major therapeutic areas include hematology, immunotherapy and critical care.
In 2025, Octapharma’s:
- Net sales reached €3.64 billion
- Operating income reached €577 million
- Net sales increased by 5%
- Operating income increased by 8.5%
- Global workforce reached 11,126 employees
The United States was the company’s main growth driver in 2025, particularly in immunoglobulins and products such as human coagulation factor VIII and 4F-PCC.
This business performance helps explain why Marguerre’s estimated fortune has grown over time.
How Wolfgang Marguerre Made His Money
Marguerre did not build his fortune through acting, music, social-media sponsorships or celebrity endorsements. His wealth is primarily the result of pharmaceutical entrepreneurship and ownership of a privately held healthcare company.
Octapharma Ownership
Octapharma is the most important source of Marguerre’s wealth.
He founded the company with Robert Taub on June 2, 1983, after the two had worked together in the plasma business at Baxter-Travenol.
The company initially focused on developing safer plasma-derived treatments, particularly for people with hemophilia. Its first factor VIII product, octavi, was launched in 1985.
Executive Leadership
Marguerre remains Chairman and CEO of Octapharma Group. His son, Tobias Marguerre, is listed as Deputy Chairman.
Because Octapharma is private, Marguerre’s personal salary and annual dividend income are not publicly reported in the way compensation is disclosed for executives of listed companies.
For that reason, assigning an exact annual salary to Marguerre would be speculative.
Long-Term Business Value
The more important factor is the value of the business itself.
Octapharma has expanded from a small pharmaceutical venture into an international healthcare group with production, research and plasma-collection operations across multiple markets. The company says its business model is based on long-term ownership rather than short-term public-market pressures.
That long-term ownership structure is central to understanding Marguerre’s wealth.
Early Life and Education
Wolfgang Marguerre was born on June 4, 1941, in Heidelberg, Germany.
He studied at Heidelberg University before earning an MBA from INSEAD in 1972. His international business education became an important foundation for a career that eventually took him into pharmaceutical management across Europe.
His professional experience in healthcare began before Octapharma existed. Rather than immediately starting his own company, Marguerre first gained experience managing pharmaceutical and plasma-related operations.
That background ultimately positioned him to identify an opportunity in the plasma-derivatives industry.
Career Journey
Early 1970s: Pharmaplast
After completing his MBA at INSEAD, Marguerre became managing director of Pharmaplast, a division of A.P. Møller in Copenhagen.
The position gave him additional experience in international pharmaceutical management.
1970s: Baxter-Travenol
Marguerre later joined Baxter-Travenol Europe in Brussels, where he became director and business manager of the Hyland division.
This stage of his career was particularly significant because he met Robert Taub, who would later become his business partner at Octapharma.
Octapharma’s own historical account says Marguerre and Taub first crossed paths at Baxter’s Travenol Laboratories while working in the plasma-derived healthcare field.
1979: Revlon Healthcare
In 1979, Marguerre moved to the Revlon Healthcare Group in Paris, becoming Senior Executive Vice President and taking responsibility for the company’s plasma division.
His experience at Revlon further deepened his understanding of plasma-based therapies and the international pharmaceutical market.
1983: Founding of Octapharma
The defining moment of Marguerre’s career came on June 2, 1983, when he and Robert Taub founded Octapharma in Switzerland.
The company’s founding was driven partly by concerns over the safety of plasma-derived treatments available to hemophilia patients during a period when hepatitis and HIV posed serious risks.
Marguerre and Taub pursued technology designed to improve viral safety in plasma-derived medicines.
1985: First Factor VIII Product
Octapharma launched its first factor VIII product, octavi, in 1985.
Factor VIII is an essential treatment for people with hemophilia A, making the company’s early focus highly relevant to the healthcare needs it was established to address.
1989: Vienna Manufacturing Expansion
A major turning point came in 1989 when Octapharma acquired its first fractionation plant in Vienna.
According to the company’s historical account, the acquisition transformed Octapharma from a 12-person operation into a business with approximately 150 employees and its own manufacturing facility.
1995: Marguerre Takes Full Control
Marguerre and Taub eventually went their separate ways as business partners.
In 1995, Taub sold his stake in Octapharma to Marguerre. By then, Octapharma had annual sales of approximately €100 million, according to the company’s historical account.
This transaction was crucial to Marguerre’s eventual fortune because it increased his ownership position in the company that would become the foundation of his wealth.
2003–2004: Expansion in the United States
Octapharma received U.S. FDA approval for intravenous human normal immunoglobulin in 2003 and subsequently established Octapharma USA in 2004.
The U.S. market later became a major contributor to the group’s global sales.
2023: 40 Years of Octapharma
Octapharma celebrated its 40th anniversary in 2023, marking four decades since Marguerre and Taub founded the company.
2025: Record Financial Performance
Octapharma reported record results for 2025, with €3.64 billion in net sales and €577 million in operating income.
2026: $7.8 Billion Estimated Fortune
Forbes’ September 7, 2026 estimate places Wolfgang Marguerre and his family at $7.8 billion.
Major Achievements
Building a Global Pharmaceutical Company
Marguerre’s most important achievement is the transformation of Octapharma from a small 1983 startup into a major international healthcare company.
Octapharma now describes itself as the world’s largest privately owned and independent plasma fractionator.
Long-Term Leadership
Marguerre has remained deeply involved in the company for more than four decades and continues to serve as Chairman and CEO.
Pharmaceutical Innovation
Octapharma’s portfolio includes therapies involving immunoglobulins, coagulation factors and other human protein medicines used in areas such as hematology, immunotherapy and critical care.
International Recognition
Marguerre has received major European honors, including the Légion d’honneur from France in 2009 and Austria’s Great Golden Decoration of Honour for Services to the Republic of Austria in 2011.
Honorary Citizen of Heidelberg
In November 2023, the City of Heidelberg named Marguerre an honorary citizen in recognition of his contributions to the city, including support for culture, education, medicine, science and social projects.
Assets and Lifestyle
There is limited reliable public information about Wolfgang Marguerre’s complete personal asset portfolio.
Forbes lists Heidelberg, Germany, as his residence.
Unlike some billionaire profiles, there is no strong evidence base for assigning specific values to private aircraft, yachts, multiple luxury homes or art collections. Those claims should not be presented as facts without documentation.
The clearest conclusion is that Marguerre’s wealth is concentrated around pharmaceutical business ownership, rather than being primarily derived from a highly public luxury lifestyle.
Philanthropy and Heidelberg Legacy
Philanthropy is an important but sometimes overlooked part of Marguerre’s biography.
Heidelberg Theatre
Marguerre has made major contributions to the Theater und Orchester Heidelberg.
The City of Heidelberg reported that private supporters and companies contributed around €19 million toward the theatre’s renovation, with Marguerre contributing more than €15 million. The newly created hall was named the Wolfgang Marguerre-Saal in recognition of his support.
Earlier in the project, the city reported that Marguerre had committed €13 million to the theatre renovation and later contributed another €750,000 toward a lifting platform for the Old Hall.
Cultural and Civic Giving
Heidelberg recognized Marguerre in 2023 for longstanding support of culture, education, medicine, science and social projects in the city.
His relationship with Heidelberg therefore extends beyond business. He has become a significant private patron of the city’s cultural and civic institutions.
Save One Life
Octapharma is also a leading corporate sponsor of Save One Life, an international nonprofit supporting children and adults living with bleeding disorders. Forbes identifies this as part of Octapharma’s philanthropic involvement.
Personal Life
Wolfgang Marguerre is married and has three children, according to Forbes.
His family is closely connected with Octapharma’s ownership and leadership structure. His son Tobias Marguerre serves as Deputy Chairman of Octapharma Group, while Wolfgang Marguerre remains Chairman and CEO.
Marguerre has maintained a strong connection to Heidelberg throughout his life and business career. His civic involvement has made him one of the city’s most prominent private philanthropists.
His personal life otherwise remains relatively private, with limited reliable public information about his family beyond the details disclosed by reputable sources.
Wolfgang Marguerre Net Worth Growth Timeline
Because Octapharma is privately held, historical billionaire figures should be treated as estimates rather than audited personal wealth figures.
| Period | Estimated Wealth | Important Context |
| 1983 | Not publicly established | Octapharma founded |
| 1995 | Not publicly established | Marguerre acquired Robert Taub’s stake |
| 2003–04 | Not publicly established | Expansion into the U.S. market |
| 2023 | Billionaire-level fortune | Octapharma marked 40 years |
| 2025 | About $7B range in published estimates | Continued business expansion and record results |
| Sept. 2026 | $7.8 billion | Latest Forbes real-time estimate |
The exact historical values are difficult to compare because billionaire rankings use different methodologies, valuation dates and assumptions.
Why Wolfgang Marguerre’s Net Worth Changes
Several factors can affect Marguerre’s published net-worth estimate.
Octapharma’s Valuation
The value of a privately held company is estimated rather than determined by a daily stock-market price.
Business Performance
Octapharma’s 2025 record results demonstrate the scale of the business. Revenue increased to €3.64 billion while operating income reached €577 million.
Family Ownership
Forbes reports the fortune as “Wolfgang Marguerre & family,” rather than simply Wolfgang Marguerre.
Currency Exchange Rates
Octapharma reports its financial performance in euros, while Forbes’ billionaire estimates are presented in U.S. dollars. Changes in exchange rates can therefore affect the dollar value attributed to the fortune.
Private-Market Estimates
Different publications can arrive at different figures because their valuation models and available information differ.
Interesting Facts About Wolfgang Marguerre
- He was born in Heidelberg, Germany, in 1941.
- He earned an MBA from INSEAD in 1972.
- He worked at Baxter-Travenol before founding Octapharma.
- He worked for Revlon Healthcare before establishing his own company.
- He co-founded Octapharma in 1983 with Robert Taub.
- Marguerre later acquired Taub’s stake in Octapharma in 1995.
- Octapharma remains a family-owned business.
- His son Tobias Marguerre is Octapharma’s Deputy Chairman.
- He has been a major supporter of the Heidelberg Theatre.
- The theatre’s new hall is named the Wolfgang Marguerre-Saal.
- Heidelberg made him an honorary citizen in 2023.
- Forbes estimates his family fortune at $7.8 billion in September 2026.
FAQs
What is Wolfgang Marguerre’s net worth in 2026?
Wolfgang Marguerre and his family are estimated to be worth $7.8 billion as of September 7, 2026, according to Forbes.
How did Wolfgang Marguerre become a billionaire?
He built his fortune primarily through Octapharma, the pharmaceutical company he co-founded in 1983 and later gained greater ownership of after Robert Taub sold his stake in 1995.
Who owns Octapharma?
Octapharma has been family-owned since 1983. Wolfgang Marguerre remains Chairman and CEO, while Tobias Marguerre is Deputy Chairman.
Is Wolfgang Marguerre still CEO of Octapharma?
Yes. Octapharma currently lists Wolfgang Marguerre as Chairman and CEO of the Octapharma Group.
How old is Wolfgang Marguerre?
Wolfgang Marguerre is 85 years old in 2026, having been born on June 4, 1941. Forbes currently lists his age as 85.
What does Octapharma do?
Octapharma develops and manufactures human protein medicines derived from human plasma and human cell lines, with major activities in hematology, immunotherapy and critical care.
How much revenue does Octapharma generate?
Octapharma reported €3.64 billion in net sales for 2025, a 5% increase from the previous year. Operating income reached €577 million.
Is Octapharma publicly traded?
No. Octapharma is a privately owned pharmaceutical company, so it does not have a publicly quoted market capitalization like a listed pharmaceutical company.
Where does Wolfgang Marguerre live?
Forbes lists Heidelberg, Germany, as his residence.
Who are Wolfgang Marguerre’s children?
Forbes reports that Wolfgang Marguerre has three children. His son Tobias Marguerre is Deputy Chairman of Octapharma Group.
What awards has Wolfgang Marguerre received?
His honors include France’s Légion d’honneur, awarded in 2009, and Austria’s Great Golden Decoration of Honour for Services to the Republic of Austria, awarded in 2011.
How much did Wolfgang Marguerre donate to the Heidelberg Theatre?
The City of Heidelberg says Marguerre contributed more than €15 million to the theatre renovation. The new hall was subsequently named the Wolfgang Marguerre-Saal.
Why is Wolfgang Marguerre’s net worth different across websites?
His fortune is tied largely to a privately held company, so different publications can use different valuation methods. Forbes’ latest estimate is $7.8 billion, while older sources may show lower figures based on earlier valuation dates.
Final Takeaway
Wolfgang Marguerre built his wealth through decades of experience in the pharmaceutical industry and the success of Octapharma, the company he co-founded in 1983. His journey from working in senior pharmaceutical roles to leading a global healthcare company shows the importance of long-term business growth and industry expertise.
Today, Octapharma is a major privately owned pharmaceutical company with operations around the world. Its strong financial performance has played an important role in Marguerre’s estimated $7.8 billion net worth in 2026. His son, Tobias Marguerre, is also involved in the company’s leadership, helping continue the family’s business legacy.
Beyond business, Marguerre is known for supporting cultural, educational, medical, and social initiatives, particularly in Heidelberg. Overall, his career combines pharmaceutical entrepreneurship, family business ownership, international expansion, and philanthropy.
Suggested Internal Links
- Gabe Newell Net Worth: Powerful $10.2B Fortune in 2026
- Falguni Nayar Net Worth: Inside Her Powerful $5.3B Fortune
2 thoughts on “Wolfgang Marguerre Net Worth: The Remarkable Rise of an $7.8 Billion Fortune”